Post mortem validation and mechanistic study of UCB‐J in progressive supranuclear palsy patients’ brains
Alzheimer's & Dementia · 2025-02 · 21 (2)
DOI: 10.1002/alz.14409 ↗Kurz gefasst
Validierungsstudie in der Zeitschrift Alzheimer's & Dementia, online erschienen am 13.12.2024. Verfasst von Miriam Scarpa und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Clinical Geriatrics, Center for Alzheimer Research, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockho…. Hauptthemen laut MEDLINE: Supranuclear Palsy, Progressive, Brain. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Swedish Research Council, the Stockholm County Council - Karolinska Institute Regional Agreement on Medical Training and Clinical Research (ALF grant), Hjärnfonden.
Abstract (Originalsprache)
INTRODUCTION Progressive supranuclear palsy (PSP) is a devastating 4R tauopathy affecting motor functions and is often misdiagnosed/underdiagnosed due to a lack of specific biomarkers. Synaptic loss is an eminent feature of tauopathies including PSP. Novel synaptic positron emission tomography tracer UCB‐J holds great potential for early diagnosis; however, there is a substantial knowledge gap in terms of the mechanism and the extent and nature of synaptic loss in PSP. METHODS Here, we report an in‐depth post mortem validation and mechanistic study of UCB‐J in PSP and control brains using radioligand/autoradiography binding studies, alongside biochemical correlation analyses of synaptic markers. RESULTS AND DISCUSSION 3 H‐UCB‐J targeted synaptic vesicle protein 2A protein with high specificity and demonstrated a distinct interrelation with synaptic markers in PSP patients’ brain regions. The loss of UCB‐J binding in the early and severely affected globus pallidus of PSP patients’ brains revealed deficits of glutamate/GABAergic synaptic terminals. Cortical and subcortical 4R tau load differentially impacted synaptic marker profiles across PSP patients, warranting further investigation. Highlights UCB‐J targeted synaptic vesicle protein 2A with high specificity in progressive supranuclear palsy (PSP) brains and demonstrated a conserved single nM binding site across different brain regions. UCB‐J depicted prominent synaptic loss at the synaptosome levels and revealed deficits of glutamate/GABAergic synaptic terminals in the early affected globus pallidus of PSP brains as compared to the control. Cortical and subcortical 4R tau load distinctly influenced synaptic markers profile across PSP patients and highlighted that presynaptic “ubiquitous” markers individually might not be able to represent the complete state of synaptic deficits/loss in PSP brains.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Clinical Geriatrics, Center for Alzheimer Research, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden.
- Department of Biology, University of Crete, Heraklion, Greece.
- Department of Medical Sciences, Faculty of Medicine, University of Girona, Girona, Spain.
- Faculty of Pharmacy, Hacettepe University, Ankara, Turkey.
- Theme Inflammation and Aging, Karolinska University Hospital, Stockholm, Sweden.
ORCID-Profile: Miriam Scarpa
Förderung
- Swedish Research Council
- the Stockholm County Council - Karolinska Institute Regional Agreement on Medical Training and Clinical Research (ALF grant)
- Hjärnfonden
- Gamla Tjänarinnor Foundation
- Magnus Bergvall's Foundation
- Demensfonden
- Stiftelsen Sigurd och Elsa Goljes Minne
- the Center for Innovative Medicine (CIMED) Region Stockholm
Zitieren
APA
Scarpa, M., Vallera, E., Ausellé-Bosch, S., Rocha, F. M., Mercan, B. E., Roy, A., Nordberg, A., & Kumar, A. (2025). Post mortem validation and mechanistic study of UCB‐J in progressive supranuclear palsy patients’ brains. Alzheimer's & Dementia, 21(2). https://doi.org/10.1002/alz.14409
Vancouver
Scarpa M, Vallera E, Ausellé-Bosch S, Rocha FM, Mercan BE, Roy A, et al. Post mortem validation and mechanistic study of UCB‐J in progressive supranuclear palsy patients’ brains. Alzheimer's & Dementia. 2025;21(2). doi:10.1002/alz.14409
BibTeX
@article{Scarpa2025,
author = {Scarpa, Miriam and Vallera, Elisavet and Ausellé-Bosch, Sira and Rocha, Filipa M and Mercan, Buse Esra and Roy, Avishek and Nordberg, Agneta and Kumar, Amit},
title = {Post mortem validation and mechanistic study of UCB‐J in progressive supranuclear palsy patients’ brains},
journal = {Alzheimer's & Dementia},
year = {2025},
volume = {21},
number = {2},
doi = {10.1002/alz.14409}
}
EUVIMED